Technetium-99m Diphosphonate Retention in Hyperparathyroidism
Authors: HUNTER HEATH
Journal: Annals of Internal Medicine (1980)

Letters and Corrections1 June 1980Technetium-99m Diphosphonate Retention in HyperparathyroidismHUNTER HEATH III, M.D.HUNTER HEATH III, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-92-6-873 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Fogelman and colleagues (1) show increased total-body retention of technetium-99m diphosphonate in a small group of patients with primary hyperparathyroidism and equate this finding with evidence of "skeletal disease." They propose this as a ". . . simple, sensitive . . . test in the diagnosis and evaluation of . . . suspected primary hyperparathyroidism." In my opinion, their logic is flawed and their conclusions premature, if not inappropriate. Several specific criticisms follow.1. The authors state that their method "can differentiate patient groups with renal osteodystrophy, osteomalacia, Paget's disease, and primary hyperparathyroidismfrom a control population"...References1. FOGELMANBESSENTBEASTALLBOYLE IRGI. Estimation of skeletal involvement in primary hyperparathyroidism: use of 24-hour whole-body retention of technetium-99m diphosphonate. Ann Intern Med. 1980;92:65-7. LinkGoogle Scholar2. HEATHHODGSONKENNEDY HSM. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302:189-93. CrossrefMedlineGoogle Scholar3. BARZEL U. The changing face of hyperparathyroidism. Hosp Pract. 1977;12:89-94. CrossrefMedlineGoogle Scholar4. BRADLEYDI GIROLAMOGOLDMANMCLARIN EMAC. Serum parathormone in the identification and surgical management of hyperparathyroidism. South Med J 1978;71:1234-7. CrossrefMedlineGoogle Scholar1. FOGELMANBESSENTTURNERCITRINBOYLEGREIG IRJDIW. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270-5. MedlineGoogle Scholar2. FOGELMANBESSENTBEASTALLBOYLE IRGI. Estimation of skeletal involvement in primary hyperparathyroidism: use of 24-hour whole-body retention of technetium-99m diphosphonate. Ann Intern Med. 1980;92:65-7. LinkGoogle Scholar3. DI BELLAKEHRWALDLAAKSOZITNER FJKL. Parathyrin radioimmunoassay: diagnostic utility of antisera produced against carboxyl-terminal fragments of the hormone from the human. Clin Chem. 1978;24:451-4. CrossrefMedlineGoogle Scholar4. ARNAUDTSAOLITTLEDIKE CHT. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest. 1971;50:21-34. CrossrefMedlineGoogle Scholar5. HEATHHODGSONKENNEDY HSM. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302:189-93. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HUNTER HEATHIII, M.D.Affiliations: Mayo Clinic Rochester, MN 55901 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1980Volume 92, Issue 6Page: 873-874KeywordsHyperparathyroidismRenal diseases ePublished: 1 December 2008 Issue Published: 1 June 1980 PDF downloadLoading ...